Featured Press Releases
ICER Publishes Final Evidence Report and Policy Recommendations on Aducanumab for Alzheimer’s Disease
Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net health benefit.
08/05/2021ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020In Landmark International Program, HTA Agencies Around the World Access ICER’s Customizable COVID-19 Cost-Effectiveness Model
Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform Ministerial recommendations on remdesivir; other HTA agencies and research groups in the United Kingdom, Australia, Canada and South Africa plan to access the model.
10/09/2020